| Diana Choi, PA-C | |
|
39th Medical Group, Unit 7095, Apo, AE 09824-5185 | |
| (314) 676-7259 | |
| Not Available |
| Full Name | Diana Choi |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Location | 39th Medical Group, Unit 7095, Apo, Armed Forces Europe |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609427012 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Diana Choi, PA-C 39th Medical Group, Unit 7095, Apo, AE 09824-5185 Ph: () - | Diana Choi, PA-C 39th Medical Group, Unit 7095, Apo, AE 09824-5185 Ph: (314) 676-7259 |
News Archive
Today AbbVie announced the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option available in all 28 member states of the European Union for the treatment of Waldenstrom's macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.
You can do a lot in four years: go from white to black belt in taekwondo, plant a dwarf apple tree and pick its fruit, see your grandchild off to college and attend her graduation or get your own degree.
Opexa Therapeutics, Inc., a company developing Tovaxin, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that Neil K. Warma, Opexa's president and chief executive officer, will deliver a corporate presentation at Rodman & Renshaw's 11th Annual Healthcare Conference.
A new study describes the complexity of the new T cell repertoire following immune-depleting therapy to treat multiple sclerosis, improving our understanding of immune tolerance and clinical outcomes.
A new study has confirmed that the drug, ivacaftor (VX-770), significantly improves lung function in some people with cystic fibrosis (CF). The results of the phase III clinical trial study, "A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation," led by Bonnie W. Ramsey, MD of Seattle Children's Research Institute and the University of Washington, were published today in the New England Journal of Medicine.
› Verified 4 days ago
Jeffrey Robert Hartzell, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 86 Mdg, Unit 3215, Ramstein Ab, Apo, AE 09094 Phone: 314-480-4758 | |
Mr. Francis Edward Criss Jr., PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: Hq, Meddac Bavaria, Unit 28037 Bldg 700, Apo, AE 09112 Phone: 910-907-8922 | |
Jason Mommaerts, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 86 Mdg, Unit 3215, Apo, AE 09094 Phone: 314-480-7520 | |
Ms. Nancy Marie Giunta, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: Lrmc, Cmr 402, Box 1917, Apo, AE 09180 Phone: 486-820-2 | |
Ms. Karyn Elizabeth Kagel, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: Landstuhl Regional Medical Center, Unit 3310,0, Apo, AE 09180 Phone: 314-542-3918 | |
Brandon Burt, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: Us Army Meddac Bavaria, Cmr 411, Bldg 700, Rm 41, Apo, AE 09112 Phone: 734-787-1619 | |
Sean Kelly, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: Cmr 411 Box 2507, Apo, AE 09112 Phone: 216-990-2375 |